Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crossover pharmacokinetic comparison of intranasal and sublingual fentanyl in breakthrough cancer pain
NL-OMON44451Withdrawn
- Sponsor
- Reinier de Graaf Hospital
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fentanyl in breakthrough cancer pain (BTcP) (2 arms), sponsored by Reinier de Graaf Hospital. Primary endpoint: Pharmacokinetic parameters of intranasal and sublingual fentanyl. Planned start May 2015; status: withdrawn.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NL-OMON44451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44451.